Most cancer patients never hear the truth: access to care doesn’t mean access to the best care.

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, breaks down why standard cancer treatment often fails to deliver long-term results. Built around population averages, insurance billing, and hospital revenue models — not the patient — most protocols overlook the thousands of genetic and immune markers that determine how your body responds to treatment.

Dr. Prato explains how multi-omics deep mapping (DNA, RNA, immune, and spatial biology) reveals the true drivers of your cancer and how immune-centric, precision-built care can transform outcomes. This episode dives into how Envita’s precision ecosystem custom-builds drug combinations, delivery systems, and immune retraining to help patients achieve durable remission — not just short-term control.

🎯 What You’ll Learn in This Episode:
• Why standard of care treats population averages, not individuals
• How multi-omics testing (DNA, RNA, immune, spatial biology) changes treatment outcomes
• The difference between cytostatic (slowing) and cytotoxic (killing) therapies
• How immune-centric care “turns cold tumors hot” for better response
• Why adaptive real-time monitoring helps prevent relapse
• The key questions every cancer patient should ask before starting treatment

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak to a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

She was 67, a grandmother, diagnosed with Stage IV ER/PR-positive, HER2-negative breast cancer — with metastases through her bones. Standard chemotherapy left her devastated: fatigue, nausea, hair loss, neuropathy, and no lasting results. She vowed never again.

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, shares how precision oncology changed everything. Using deep mapping (DNA, RNA, immune, and spatial biology), his team discovered blocked immune pathways and stromal barriers — the “walls” preventing chemo and immune cells from reaching the cancer.

Through genetically targeted fractionated chemotherapy (GTF), image-guided interventional oncology, and immune retraining with NK and dendritic cells, this grandmother achieved what she wanted most — real healing without the suffering. In 14 weeks, bone pain was gone, energy returned, and her life reignited.

🎯 What You’ll Learn in This Episode:
• Why HER2-negative, hormone-resistant breast cancers are harder to treat
• How deep DNA/RNA mapping finds hidden resistance pathways
• What stromal barriers are — and how to break them
• How microdosed chemo and direct tumor delivery reduce toxicity
• Why immune retraining helps achieve lasting remission
• The six essential questions every cancer patient should ask their doctor

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak to a care coordinator: 866-830-4576

“This wasn’t luck — it was precision. And precision changes everything.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

Glioblastoma multiforme (GBM) is one of the hardest cancers in the world to treat — not just because it grows fast, but because it spreads like hidden tentacles throughout the brain and hides behind the blood–brain barrier.

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains why GBM keeps coming back even after surgery, radiation, and temozolomide — and how deep multi-omics mapping, smart drug delivery, and immune-centric therapy can change the fight. Using the story of a patient we’ll call Tom, Dr. Prato breaks down how DNA sequencing, RNA transcriptomics, immune spatial biology, and targeted immunotherapy work together to overcome resistance, penetrate the blood–brain barrier, and awaken the body’s natural killer cells.

You’ll learn how strategies like genetically targeted fractionated chemotherapy (GTF), AAIT cellular biologics, oncolytic viruses, methylene blue mitochondrial support, and phytotherapeutics help turn a cold, invisible GBM into a hot, immune-responsive target — all while improving quality of life and real-time monitoring with CTCs and methylation scores.

🎯 What You’ll Learn in This Episode:
• Why GBM returns even after surgery, radiation & temozolomide
• How DNA, RNA & immune spatial biology reveal hidden tumor pathways
• Why the blood–brain barrier blocks many standard drugs
• How microdosed, genetically targeted chemo activates DAMP signaling
• The role of NK cells, dendritic cells & AAIT in immune-centric GBM care
• How mitochondrial repair (cytochrome C, methylene blue, vitamin C) restores apoptosis
• Why gut health plays a critical role in brain-immune function

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak to a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493